Document is current
Any future updates will be listed below
-
Authors
Svendstrup, Mathilde https://orcid.org/0000-0002-9176-1707
Rasmussen, Aase Krogh https://orcid.org/0000-0002-9729-4767
Kistorp, Caroline https://orcid.org/0000-0002-3019-6775
Klose, Marianne https://orcid.org/0000-0001-6075-0821
Andreassen, Mikkel https://orcid.org/0000-0002-1656-3516
-
Funding
Funding for this research was provided by:
National Hospital
- License Information
-
More Information
Article History
Accepted: 9 July 2024
First Online: 9 August 2024
Declarations
:
: This is an observational study including retrospective data collected from patient files as part of their regular controls in the clinic. All participants filled out informed consent declarations giving accept to have their data collected, analyzed and the results to be published. The study was approved by the Danish Data Protection Agency and did not require acceptance of the Ethics committee. Prior to the authorization of semaglutide for obesity treatment by the European Medicines Agency in January 2022, its use in our clinic was approved and subsidized by the Danish Medicines Agency.
: CK has served on scientific advisory panels and or received speaker fees from Boehringer Ingelheim, Astra Zeneca, Novo Nordisk, Novartis Genzyme, Amicus, and Chiesi. MS, AKR, MK and MA have no conflicts of interests to declare.
: Gudmundur Johansson, Professor at the Institute of Medicine, University of Gothenburg, gudmundur.johannsson@medic.gu.se. Pia Burman, Physician at Translational Muscle Research, Lund University, pia.burman@med.lu.se.
